# **ANALYSIS OF DRUGS INTERACTIONS BETWEEN CORONAVIRUS (COVID-19) ANTIVIRAL TREATMENT AND CONCOMITANT MEDICATION**

R. Castillejo García, N. Martin Fernández, M. Beltrán García, A. Martínez Suarez, L. Rendón de Lope, S. Sandoval Fernández del Castillo. Hospital Universitario Virgen Macarena. Hospital Pharmacy. Seville, Spain. 4CPS-260

## **BACKGROUND AND IMPORTANCE**

Drugs used for covid (lopinavir/ritonavir, hydroxychloroquine) have a large number of interactions. If any of these drugs are used, we should be cautious and monitor the clinical evolution of each patient closely.

# **AIM AND OBJECTIVES**

To analyse potential drug interactions of the treatment for COVID-19 and to evaluate physician acceptance of pharmacist recommendation.


## **MATERIAL AND METHODS**

#### Prospective interventional study from March to May 2020

Patients who started antiviral treatment for COVID-19 with positive PCR and hospital admission

Data was collected from **DIRAYA®** and **PRISMA®** 






#### RESULTS

- **178 patients** (56.2% men)
- Median age of 63 [range 22-90] years
- 267 interactions were detected (56.9% moderate / 43.1% major)
- The MI involved was: pharmacokinetic (63.9%) / pharmacodynamic (36.1%)
- 22,8% of the collected drugs may affect QT interval
- Antiviral therapy: lopinavir/ritonavir (96,6%) and hydroxychloroquine (94,9%)

72.5% of the patients had at least one interaction

15,7% selective calcium channel blockers 11,2% topical nasal corticosteroids 10,5% angiotensin II receptor blockers 8,8% HMG-COA reductase inhibitors







#### CONCLUSION

Pharmacist participation in the multidisciplinary team COVID was relevant for the detection of multiple interactions, helping doctors in decision-making about drugs not commonly used in an overwhelmed healthcare situation.

#### REFERENCES

https://www.drugs.com https://www.druginteractions.org/



**Hospital Universitario** Virgen Macarena